Incyte Corporation (INCY)
Company Info
| ISIN | US45337C1027 |
|---|---|
| CUSIP | 45337C102 |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | Nov 4, 1993 |
Highlights
| Market Cap | $15.71B |
|---|---|
| EPS (TTM) | $0.09 |
| PE Ratio | 905.89 |
| PEG Ratio | 0.69 |
| Total Revenue (TTM) | $4.08B |
| Gross Profit (TTM) | $3.77B |
| EBITDA (TTM) | $157.29M |
| Year Range | $50.35 - $83.95 |
| Target Price | $77.34 |
| Short % | 6.77% |
| Short Ratio | 3.86 |
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Popular comparisons: INCY vs. SPY, INCY vs. SMH, INCY vs. PDD, INCY vs. ILMN
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Incyte Corporation, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Returns By Period
Incyte Corporation had a return of 28.17% year-to-date (YTD) and 47.48% in the last 12 months. Over the past 10 years, Incyte Corporation had an annualized return of 1.47%, while the S&P 500 had an annualized return of 11.39%, indicating that Incyte Corporation did not perform as well as the benchmark.
| Period | Return | Benchmark |
|---|---|---|
| Year-To-Date | 28.17% | 25.48% |
| 1 month | 22.98% | 2.14% |
| 6 months | 41.07% | 12.76% |
| 1 year | 47.48% | 33.14% |
| 5 years (annualized) | -1.48% | 13.96% |
| 10 years (annualized) | 1.47% | 11.39% |
Monthly Returns
The table below presents the monthly returns of INCY, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | -6.40% | -0.70% | -2.38% | -8.64% | 11.03% | 4.90% | 7.34% | 0.91% | 0.67% | 12.13% | 28.17% | ||
| 2023 | 6.00% | -9.58% | -6.12% | 2.96% | -17.28% | 1.14% | 2.36% | 1.27% | -10.48% | -6.65% | 0.76% | 15.55% | -21.83% |
| 2022 | 1.27% | -8.11% | 16.28% | -5.62% | 1.24% | 0.11% | 2.25% | -9.33% | -5.38% | 11.55% | 7.17% | 0.82% | 9.43% |
| 2021 | 3.18% | -12.36% | 3.32% | 5.06% | -1.87% | 0.42% | -8.06% | -1.11% | -10.08% | -2.62% | 1.10% | 8.39% | -15.61% |
| 2020 | -16.32% | 3.20% | -2.89% | 33.36% | 4.35% | 2.02% | -5.01% | -2.44% | -6.86% | -3.45% | -2.42% | 2.89% | -0.39% |
| 2019 | 26.73% | 7.00% | -0.26% | -10.71% | 2.38% | 8.05% | -0.05% | -3.65% | -9.28% | 13.05% | 12.20% | -7.26% | 37.32% |
| 2018 | -4.67% | -5.68% | -2.15% | -25.67% | 10.22% | -1.86% | -0.69% | 11.08% | -6.53% | -6.17% | -0.88% | -1.03% | -32.86% |
| 2017 | 20.88% | 9.81% | 0.43% | -7.02% | 4.06% | -2.64% | 5.86% | 3.09% | -15.04% | -2.99% | -12.59% | -4.32% | -5.55% |
| 2016 | -34.94% | 4.17% | -1.40% | -0.28% | 16.80% | -5.25% | 12.79% | -10.10% | 16.26% | -7.76% | 17.62% | -1.97% | -7.54% |
| 2015 | 9.03% | 7.70% | 6.77% | 6.00% | 13.37% | -5.39% | 0.07% | 11.42% | -5.04% | 6.53% | -2.80% | -5.07% | 48.34% |
| 2014 | 29.41% | -1.92% | -16.71% | -9.27% | 2.04% | 13.91% | -15.72% | 13.94% | -9.50% | 36.72% | 12.66% | -3.23% | 44.40% |
| 2013 | 10.66% | 20.95% | 5.31% | -5.38% | 0.09% | -0.77% | 6.41% | 44.77% | 12.57% | 2.23% | 19.49% | 8.65% | 204.82% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current risk-adjusted rank of INCY is 79, placing it in the top 21% of stocks on our website in terms of risk-adjusted performance. This ranking is based on the combined values of the indicators listed below.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Incyte Corporation (INCY) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Worst Drawdowns
The table below displays the maximum drawdowns of the Incyte Corporation. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Incyte Corporation was 98.54%, occurring on Mar 9, 2009. Recovery took 2016 trading sessions.
The current Incyte Corporation drawdown is 47.28%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -98.54% | Feb 28, 2000 | 2270 | Mar 9, 2009 | 2016 | Mar 10, 2017 | 4286 |
| -67.12% | Feb 5, 1998 | 420 | Oct 5, 1999 | 56 | Dec 23, 1999 | 476 |
| -66.47% | Mar 16, 2017 | 1790 | Apr 25, 2024 | — | — | — |
| -41.98% | Feb 20, 1997 | 49 | Apr 30, 1997 | 95 | Sep 15, 1997 | 144 |
| -38.89% | Feb 11, 1994 | 47 | Apr 20, 1994 | 155 | Dec 1, 1994 | 202 |
Volatility
Volatility Chart
The current Incyte Corporation volatility is 12.97%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Financials
Financial Performance
Valuation
The Valuation section provides an assessment of the market value of Incyte Corporation compared to its peers in the Biotechnology industry.
PE Ratio
The chart displays the price to earnings (P/E) ratio for INCY in comparison to other companies of the Biotechnology industry. Currently, INCY has a PE value of 905.9. This PE ratio is much higher than those of other companies of the industry. This might be an indicator of the company being overvalued.PEG Ratio
The chart displays the price to earnings to growth (PEG) ratio for INCY in comparison to other companies of the Biotechnology industry. Currently, INCY has a PEG value of 0.7. This PEG ratio is much higher than those of other companies of the industry. This might be an indicator of the company being overvalued.Historical P/E Ratio Chart
The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Incyte Corporation.
Loading data...
Income Statement
| TTM | |
|---|---|
| Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
| Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
| Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |